Tetraphase Pharmaceuticals (TTPH) Receiving Somewhat Favorable Media Coverage, Report Shows
News stories about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have been trending somewhat positive on Tuesday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tetraphase Pharmaceuticals earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.0323035269308 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern’s rankings:
- Prominent Healthcare stock of Market- Tetraphase Pharmaceuticals, Inc. (TTPH) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Analysts Expect Tetraphase Pharmaceuticals, Inc. (TTPH) Will Announce Quarterly Sales of $2.26 Million (americanbankingnews.com)
- Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index (finance.yahoo.com)
- Ahead Momentum: Compania de Minas Buenaventura SAA (BVN), Tetraphase Pharmaceuticals, Inc. (TTPH) – Market Movers (financialqz.com)
Shares of Tetraphase Pharmaceuticals (TTPH) opened at $5.98 on Tuesday. Tetraphase Pharmaceuticals has a 1 year low of $3.57 and a 1 year high of $9.93.
Several analysts have commented on the stock. BidaskClub raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Finally, HC Wainwright boosted their target price on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $15.15.
In related news, insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director L Patrick Gage acquired 3,880 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the completion of the acquisition, the director now owns 38,880 shares in the company, valued at approximately $250,776. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Receiving Somewhat Favorable Media Coverage, Report Shows” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/tetraphase-pharmaceuticals-ttph-receiving-somewhat-favorable-media-coverage-report-shows/1772897.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.